Hostname: page-component-745bb68f8f-grxwn Total loading time: 0 Render date: 2025-01-22T17:07:40.388Z Has data issue: false hasContentIssue false
  • English
  • Français

Huntington’s Disease: Recent Advances in Diagnosis and Management

Published online by Cambridge University Press:  18 September 2015

Sarah Furtado  and
Oksana Suchowersky
Sarah Furtado*
Affiliation:
Department of Clinical Neurosciences, Faculty of Medicine, The University of Calgary, Calgary
Oksana Suchowersky*
Affiliation:
Department of Clinical Neurosciences, Faculty of Medicine, The University of Calgary, Calgary
*
Department of Clinical Neurosciences, The University of Calgary, 1403 – 29 Street N.W, Calgary, Alberta, Canada T2N 2T9
Department of Clinical Neurosciences, The University of Calgary, 1403 – 29 Street N.W, Calgary, Alberta, Canada T2N 2T9
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Huntington’s Disease (HD) is a progressive degenerative disorder of the central nervous system inherited as an autosomal dominant trait. Clinically, the disorder is characterized by choreoathetosis (with age of onset typically in the late thirties or early forties) and neuropsychiatric disturbance. The striatum is particularly vulnerable to the degenerative disease process, with selective loss of medium spiny neurons and decreased levels of associated neurotransmitters, including substance P, GABA, met-enkephalin and dynorphin. Although the underlying pathophysiology is unknown, recent theories concerning pathogenesis have involved mitochondrial abnormalities and excitotoxin-mediated damage. The gene for HD has recently been discovered and characterized as an unstable CAG trinucleotide repeat sequence on the short arm of chromosome 4 (now known as IT 15). The direct test now available for the HD gene has facilitated disease diagnosis, particularly for those with unclear family history or chorea of uncertain origin; presymptomatic testing is also available. Management of affected individuals is unsatisfactory as only symptomatic control is available. However, as the effect of the genetic abnormality may soon be known, specific treatment of the disorder may become available in the near future.

Type
Review Article
Information
Canadian Journal of Neurological Sciences , Volume 22 , Issue 1 , February 1995 , pp. 5 - 12
Copyright
Copyright © Canadian Neurological Sciences Federation 1995

References

1. Huntington, G.On Chorea. Med Surg Rep 1872; 26: 317–321.Google Scholar
2. Hayden, MR.Huntington’s Disease. Berlin: Springer-Verlag, 1981: 1–12.Google Scholar
3. Harper, PS.Huntington’s Disease. London: Saunders, 1991: 1–15.Google Scholar
4. Folstein, SE, Chase, GA, Wahl, WE, et al. Huntington’s disease in Maryland: clinical aspects of racial variation. Am J Hum Genet 1987; 41: 168–179.Google ScholarPubMed
5. Shokeir, MHK.Investigations on Huntington’s disease in the Canadian prairies. I Prevalence. Clin Genet 1975; 7: 345–348.CrossRefGoogle ScholarPubMed
6. Newcombe, RG, Walker, DA, Harper, PS.Factors influencing age at onset and duration of survival in Huntington’s chorea. Ann Hum Genet 1981; 45:387–396.CrossRefGoogle ScholarPubMed
7. Bird, ED, Iversen, LL.A sex related factor in the inheritance of Huntington’s chorea. Ann Hum Genet 1974; 37: 255–260.CrossRefGoogle ScholarPubMed
8. Myers, RH, Goldman, D, Bird, ED, Sax, DS, Merril, CR, et al. Maternal transmission in Huntington’s Disease. Lancet 1988; 2: 208–210.Google Scholar
9. Young, AB, Shoulson, I, Penney, JB, et al. Huntington’s Disease in Venezuela: neurological features and functional decline. Neurology 1986; 36: 244–249.CrossRefGoogle ScholarPubMed
10. Penney, JB, Young, AB, Shoulson, I, et al. Huntington’s Disease in Venezuela: seven years of followup on symptomatic and asymptomatic individuals. MovDisord 1990; 5: 93–99.Google Scholar
11. Koller, WC, Trimble, J.The gait abnormality of Huntington’s Disease. Neurology 1985; 35: 1450–1454.CrossRefGoogle ScholarPubMed
12. Young, AB, Penney, JB, Starosta-Rubinstein, S, Markel, DS, Berent, S, et al. PET Scan investigations of Huntington’s Disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol 1986; 20: 296–303.CrossRefGoogle ScholarPubMed
13. Hefter, H, Homberg, V, Lange, HW, Freund, H-J.Impairment of rapid movement in Huntington’s Disease. Brain 1987; 110: 585–612.CrossRefGoogle ScholarPubMed
14. Folstein, SE, Leigh, J, Parhad, IM, Folstein, MF.The diagnosis of Huntington’s Disease. Neurology 1986; 36: 1279–1283.CrossRefGoogle ScholarPubMed
15. Thompson, PD, Berardelli, A, Rothwell, JC, Day, BL, Dick, JPR, et al. The coexistence of bradykinesia and chorea in Huntington’s Disease and its implications for theories of basal ganglia control of movement. Brain 1988; 111: 223–244.CrossRefGoogle ScholarPubMed
16. Lasker, AG, Zee, DS, Hain, TC, Folstein, SE, Singer, HS.Saccades in Huntington’s Disease: initiation defects and distractability. Neurology 1987; 37: 364–370.CrossRefGoogle Scholar
17. Tian, JR, Zee, DS, Lasker, AG, Folstein, SE.Saccades in Huntington’s Disease. Predictive tracking and interaction between release of fixation and initiation of saccades. Neurology 1991; 41:875–881.CrossRefGoogle ScholarPubMed
18. Sanberg, PRF, Fibiger, MC, Mark, RF.Body weight and dietary factors in Huntington’s disease patients compared with matched controls. Med J Austr 1981; 1:407–409.CrossRefGoogle ScholarPubMed
19. Walker, DP, Harper, PS, Wells, CEC, et al. Huntington’s disease in South Wales: a genetic and epidemiological study. Clin Genet 1981; 19:213–221.CrossRefGoogle Scholar
20. Folstein, SE, Abbott, MH, Chase, GA, Jensen, BA, Folstein, MF.The association of affective disorder with Huntington’s Disease in a case series and in families. Psychol Med 1983a; 13: 537–542.CrossRefGoogle Scholar
21. Folstein, SE, Franz, ML, Jensen, BA, Chase, GA, Folstein, MF.Conduct disorder and affective disorder among the offspring of patients with Huntington’s Disease. Psychol Med 1983b; 13: 45–52.CrossRefGoogle ScholarPubMed
22. Dewhurst, K, Oliver, JE, McKnight, AL.Socio-psychiatrie consequences of Huntington’s disease. Br J Psychol 1970; 16: 255–258.CrossRefGoogle Scholar
23. Ludlow, CL, Connor, NP, Bassich, CJ.Speech timing in Parkinson’s and Huntington’s Disease. Brain Lang 1987; 32: 195–214.CrossRefGoogle ScholarPubMed
24. Illes, J.Neurolinguistic features of spontaneous language production dissociate three forms of neurodegenerative diseases: Alzheimer’s, Huntington’s and Parkinson’s. Brain Lang 1989; 37: 628–642.CrossRefGoogle ScholarPubMed
25. Speedie, LJ, Brake, N, Folstein, SE, Bowers, D, Heilman, KM.Comprehension of prosody in Huntington’s Disease. J Neurol Neurosurg Psychiatry 1990; 53: 607–610.CrossRefGoogle ScholarPubMed
26. Massman, PJ, Delis, DC, Butters, N, Levin, BE, Salmon, DP.Are all subcortical dementias alike? Verbal learning and memory in Parkinson’s and Huntington’s Disease patients. J Clin Exp Neuropsychol 1990; 12(5): 729–744.CrossRefGoogle ScholarPubMed
27. Hodges, JR, Salmon, DP, Butters, N.Differential impairment of semantic and episodic memory in Alzheimer’s and Huntington’s diseases: a controlled prospective study. J Neurol Neurosurg Psychiatry 1990; 53: 1089–1095.CrossRefGoogle Scholar
28. Butters, N, Wolfe, J, Martone, M, Granholm, E, Cermak, L.Memory disorders associated with Huntington’s disease: verbal recall, verbal recognition and procedural memory. Neuropsychology 1985; 23(6): 729–743.CrossRefGoogle ScholarPubMed
29. Butters, N, Wolfe, J, Granholm, E, Martone, M.An assessment of verbal recall recognition and fluency abilities in patients with Huntington’s Disease. Cortex 1986; 22: 11–32.CrossRefGoogle ScholarPubMed
30. Butters, N, Granholm, E, Salmon, DP, Grant, I, Wolfe, J.Episodic and semantic memory: a comparison of amnesic and demented patients. J Clin Exp Neuropsychol 1987; 9: 479–497.CrossRefGoogle ScholarPubMed
31. Granholm, E, Butters, N.Associative encoding and retrieval in Alzheimer’s and Huntington’s Disease. Br Cog 1988; 7: 335–347.CrossRefGoogle ScholarPubMed
32. Heindel, WC, Salmon, DP, Butters, N.Pictorial priming and cued recall in Alzheimer’s and Huntington’s Disease. BrCog 1990; 13: 282–295.Google ScholarPubMed
33. Albert, MS, Butters, N, Brandt, J.Patterns of remote memory in amnesic and demented patients. Arch Neurol 1981; 38: 495–500.CrossRefGoogle ScholarPubMed
34. Beatty, WW.Remote memory for visuospatial information in patients with Huntington’s Disease. Psychobiology 1989; 17: 431–434.CrossRefGoogle Scholar
35. Beatty, WW, Salmon, DP, Butters, N, Heindel, WC, Granholm, EL.Retrograde amnesia in patients with Alzheimer’s or Huntington’s Disease. Neurobiol Aging 1988; 9: 181–186.CrossRefGoogle ScholarPubMed
36. Brandt, J, Butters, N.The neuropsychology of Huntington’s Disease. Trends Neurosci 1986; 9: 118–120.CrossRefGoogle Scholar
37. Fedio, P, Cox, CS, Neophytides, A, Canal-Frederick, G, Chase, TN.Neuropsychological profile of Huntington’s Disease: patients and those at risk. Adv Neurol 1979; 23: 239–255.Google Scholar
38. Sax, DS, O’Donnell, B, Menzer, L, Montgomery, K, Kayne, HL.Computed tomographic, neurologic, and neuropsychological correlates of Huntington’s Disease. Int J Neurosci 1983; 18: 21–36.CrossRefGoogle ScholarPubMed
39. Moses, JA, Golden, CJ, Berger, PA, Wisniewski, AM.Early, middle and late stage Huntington’s Disease as measured by the Luria-Nebraska neuropsychological battery. Int J Neurosci 1981; 14: 95–100.CrossRefGoogle ScholarPubMed
40. Brouwers, P, Cox, C, Martin, A, Chase, T, Fedio, P.Differential perceptual-spatial impairment in Huntington’s and Alzheimer’s dementias. Arch Neurol 1984; 41: 1073–1076.CrossRefGoogle ScholarPubMed
41. Caine, ED, Fisher, JH.Dementia in Huntington’s Disease. Hand Clin Neurol 1985; 46:305–310.Google Scholar
42. Josiassen, RC, Curry, LM, Mancall, EL.Development of neuropsychological deficits in Huntington’s Disease. Arch Neurol 1983; 40: 791–796.CrossRefGoogle ScholarPubMed
43. Knopman, D, Nissen, MJ.Procedural learning is impaired in Huntington’s Disease: evidence from the serial reaction time test. Neuropsychology 1991; 29(3): 245–254.CrossRefGoogle Scholar
44. Shelton, PA, Knopman, DS.Ideomotor apraxia in Huntington’s Disease. Arch Neurol 1991; 48: 35–41.CrossRefGoogle ScholarPubMed
45. Lyle, OE, Gottesman, II.Premorbid psychometric indicators of the gene for Huntington’s Disease. J Consult Clin Psychol 1977; 45: 1011–1022.CrossRefGoogle ScholarPubMed
46. Jason, GW, Pajurkova, EM, Suchowersky, O, Hewitt, J, Hilbert, C, et al. Presymptomatic neuropsychological impairment in Huntington’s Disease. Arch Neurol 1988; 45: 769–773.CrossRefGoogle ScholarPubMed
47. Barr, AN, Heinze, WJ, Dobben, GD.Bicaudate index in computerized tomography of HD and cerebral atrophy. Neurology 1978; 28: 1196–1200.CrossRefGoogle Scholar
48. Savoiardo, M, Strada, L, Oliva, D, et al. Abnormal MRI signal in the rigid form of Huntington’s Disease. J Neurol Neurosurg Psychiatry 1991; 54:888–891.CrossRefGoogle ScholarPubMed
49. Hayden, MR, Martin, WRW, Stoessl, AJ, et al. Positron emission tomography in the early diagnosis of Huntington’s disease. Neurology 1986; 36:888–894.CrossRefGoogle ScholarPubMed
50. Hayden, MR, Hewitt, HJ, Martin, WRW, et al. Studies in persons at risk for Huntington’s disease. N Engl J Med 1987; 317: 382–383.Google Scholar
51. Garnett, ES, Firnau, G, Nahmias, C, Carbotte, R, Bartolucci, G.Reduced striatal glucose consumption and prolonged reaction time and early features in Huntington’s Disease. J Neurol Sci 1984; 65:231–237.CrossRefGoogle ScholarPubMed
52. Kuwert, T, Lange, HW, Langen, K-J, Herzog, H, Aulich, A, et al. Cortical and subcortical glucose consumption measured by PET in patients with Huntington’s Disease. Brain 1990; 113: 1405–1423.CrossRefGoogle ScholarPubMed
53. Martin, WR, Clark, C, Ammann, W, Stoessl, AJ, Shtybel, W, et al. Cortical glucose metabolism in Huntington’s Disease. Neurology 1992; 42:223–229.CrossRefGoogle ScholarPubMed
54. Hayden, MR, Hewitt, J, Stoessl, AJ, Clark, C, Ammann, W, et al. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington’s Disease. Neurology 1985; 37: 1441–1447.CrossRefGoogle Scholar
55. Hosokawa, S, Ichiya, Y, Kuwabara, Y, Ayabe, Z, Mitsuo, K, et al. Positron emission tomography in cases of chorea with different underlying diseases. J Neurol Neurosurg Psychiatry 1987; 50: 1284–1287.CrossRefGoogle ScholarPubMed
56. Suchowersky, O, Hayden, MR, Martin, WRW, et al. Cerebral metabolism of glucose in benign hereditary chorea. MovDisord 1986; 1:33–44.Google ScholarPubMed
57. Holthoff, VA, Koeppe, RA, Frey, KA, Penney, JB, Markel, DS, et al. Positron emission tomography measures of benzodiazepine receptors in Huntington’s Disease. Ann Neurol 1993; 34: 76–81.CrossRefGoogle ScholarPubMed
58. Vonsattel, J-P, Myers, RH, Stevens, TJ, Ferrante, RJ, Bird, ED, et al. Neuropathological classification of Huntington’s Disease. J Neuropathol Exp Neurol 1985; 44(6): 559–577.Google Scholar
59. de la Monte, SM, Vonsattel, J-P, Hedley-Whyte, ET, Ulcickas, M, Richardson, EP.Global loss of cerebral cortex and white matter in Huntington’s Disease. J Neuropathol Exp Neurol 1987; 46: 342.CrossRefGoogle Scholar
60. de la Monte, SM, Vonsattel, J-P, Richardson, EP.Morphometric demonstration of atrophic changes in the cerebral cortex, white matter and neostriatum in Huntington’s Disease. J Neuropathol Exp Neurol 1988; 47(5): 516–525.CrossRefGoogle ScholarPubMed
61. Mann, DMA, Olivier, R, Snowden, JS.The topographic distribution of brain atrophy in Huntington’s Disease and progressive supranuclear palsy. Acta Neuropathol 1993; 85: 553–559.CrossRefGoogle ScholarPubMed
62. DiFiglia, M, Pasik, T, Pasik, P.Ultrastructure of Golgi-impregnated and gold-toned spiny and aspiny neurons in the monkey neostriatum. J Neurocytol 1980; 8: 471–492.CrossRefGoogle Scholar
63. Graveland, GA, Williams, RS, DiFiglia, M.Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington’s Disease. Science 1985; 227: 770–773.CrossRefGoogle ScholarPubMed
64. Graybiel, AM, Ragsdale, CW.Biochemical anatomy of the striatum. In: Emson, PC, ed. Chemical Neuroanatomy. New York: Raven Press, 1983.Google Scholar
65. Niewenhuys, R.Chemoarchitecture of the Human Brain. Berlin: Springer-Verlag, 1988.Google Scholar
66. Vincent, SR.Nitric oxide: a radical neurotransmitter in the central nervous system. Progr Neurobiol 1994; 42: 129–160.CrossRefGoogle ScholarPubMed
67. Perry, TL, Hansen, S, Kloster, M.Huntington’s chorea. Deficiency of gamma-amino butyric acid in brain. N Engl J Med 1973: 288(7): 377–342.CrossRefGoogle Scholar
68. Bird, ED, MacKay, AVP, Rayner, CN, Iversen, LL.Reduced glutamic acid-decarboxylase activity of post-mortem brain in Huntington’s Chorea. Lancet 1973; 2: 1090–1092.Google Scholar
69. Kanazawa, I, Bird, ED, Gale, JS, Iversen, LL, Jessell, TM, et al. Substance P: Decrease in substantia nigra and globus pallidus in Huntington’s Disease. Adv Neurol 1985; 23: 495–504.Google Scholar
70. Marshall, PE, Landis, DMD, Zalneraitis, EL.Studies of substance P and leu-enkephalin in Huntington’s Disease. BrRes 1983; 289: 11–26.Google ScholarPubMed
71. Grafe, MR, Forno, LS, Eng, LF.Inimunocytochemical studies of substance P and met-enkephalin in the basal ganglia and substantia nigra in Huntington’s, Parkinson’s and Alzheimer’s Diseases. J Neuropathol Exp Neurol 1985; 44(1): 47–59.CrossRefGoogle ScholarPubMed
72. Emson, PC, Arregui, A, Clement-Jones, V, Sandberg, BEB, Rossor, M.Regional distribution of methionine-enkephalin and substance P immunoreactivity in normal human brain and Huntington’s Disease. Brain Res 1980; 199: 147–160.CrossRefGoogle Scholar
73. Seizinger, BR, Liebisch, DC, Kish, SH, Arendt, RJ, Hornykiewicz, O, et al. Opioid peptides in HD: alterations in prodynorphin and proenkephalin system. Brain Res 1986; 378: 405–408.CrossRefGoogle ScholarPubMed
74. Ellison, DW, Beal, MF, Mazurek, MF, Malloy, JR, Bird, ED, et al. Amino acid neurotransmitter abnormalities in Huntington’s Disease and the quinolinic acid animal model of Huntington’s Disease. Brain 1987; 110: 1657–1673.Google Scholar
75. Beal, MF, Ellison, DW, Mazurek, MF, Swartz, KJ, Malloy, JR, et al. A detailed examination of susbtance P in pathologically graded cases of Huntington’s Disease. J Neurol Sci 1988; 84: 51–61.CrossRefGoogle Scholar
76. Storey, E, Beal, MF.Neurochemical substrates of rigidity and chorea in HD. Brain 1993; 116: 1201–1223.CrossRefGoogle Scholar
77. Albin, RL, Young, AB, Penney, JB, et al: Abnormalities of striatal projection neurones and N-methyl-D-aspartate receptors in presymptomatic Huntington’s disease. N Engl J Med 1990; 322: 1293–1298.CrossRefGoogle ScholarPubMed
78. Albin, RL, Reiner, A, Anderson, KD, et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington’s Disease. Ann Neurol 1992; 31: 425–430.CrossRefGoogle ScholarPubMed
79. Dawbarn, D, De Quidt, ME, Emson, PC.Survival of basal ganglia neuropeptide Y-somatostatin neurons in Huntington’s Disease. Brain Res 1985; 340:251–260.CrossRefGoogle ScholarPubMed
80. Ferrante, RJ, Kowall, NW, Beal, MF, Richardson, EP, Bird, ED, et al. Selective sparing of a class of striatal neurons in HD. Science 1985; 230:561–563.Google Scholar
81. Ferrante, RJ, Kowall, NW, Martin, JB, Richardson, EP.Characteristics of a selectively spared subset of neurons in HD. J Neuropathol Exp Neurol 1985; 44: 1325.CrossRefGoogle Scholar
82. Bird, ED.Chemical pathology of Huntington’s Disease. Ann Rev Pharmacol Toxicol 1980; 20: 533–551.Google Scholar
83. Ferrante, RJ, Kowall, NW, Richardson, EP Jr, et al. Topography of enkephalin, substance P and acetylcholinesterase in Huntington’s Disease striatum. Neurosci Lett 1986; 71: 283–288.CrossRefGoogle ScholarPubMed
84. Kish, SJ, Shannak, K, Hornkiewicz, O.Elevated serotonin and reduced dopamine in subregionally divided Huntington’s Disease striatum. Ann Neurol 1987; 22: 386–389.CrossRefGoogle ScholarPubMed
85. Cudkowicz, M, Kowall, NW.Degeneration of pyramidal projection neurons in Huntington’s Disease. Ann Neurol 1990; 27: 200–204.CrossRefGoogle ScholarPubMed
86. Beal, MF, Kowall, NW, Ellison, DW, Mazurek, MF, Swartz, KJ, et al. Replications of the neurochemical characteristics of Huntington’s Disease by quinolinic acid. Nature 1986; 321: 168–171.CrossRefGoogle ScholarPubMed
87. Brownell, A-L, Hantraye, P, Wullner, U, Hamberg, L, Shoup, T, et al. PET- and MRI-Based assessment of glucose utilization, dopamine receptor binding and hemodynamic changes after lesions to the caudate-putamen in primates. Exp Neurol 1994; 125:41–51.CrossRefGoogle Scholar
88. Cross, AJ, Slater, P, Reynolds, GP.Reduced high affinity glutamate uptake sites in the brains of patients with Huntington’s disease. Neurosci Lett 1986; 67:198–202.CrossRefGoogle ScholarPubMed
89. Beal, MF, Hyman, BT, Koroshetz, W.Do defects in mitochondrial energy metabolism underlie the pathology of degenerative diseases. Trends Neurosci 1993; 16(6): 125–131.CrossRefGoogle Scholar
90. Jenkins, BG, Koroshetz, WJ, Beal, MF, Rosen, BR.Evidence for impairment of energy metabolism in vivo in Huntington’s Disease using localized ‘H-NMR spectroscopy. Neurology 1993; 43: 2689–2695.CrossRefGoogle Scholar
91. Gusella, JF, Wexler, NS, Conneally, PM, Naylor, SL, Anderson, MA, et al. A polymorphic DNA marker genetically linked to Huntington’s Disease. Nature 1983; 306: 234–238.CrossRefGoogle ScholarPubMed
92. Hayden, MR, Kastelein, JJ, Wilson, RD, Hilbert, C, Hewitt, J, et al. First trimester prenatal diagnosis for Huntington’s Disease with DNA probes. Lancet 1987; 1284–1285.CrossRefGoogle ScholarPubMed
93. Evers-Kieboom, G, Siverts, A, Cassiman, JJ, Van der Berghe, H.The motivation of at-risk individuals and their partners in deciding for or against predictive testing for Huntington’s disease. Clin Genet 1989; 35:29–40.CrossRefGoogle Scholar
94. Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s Disease chromosomes. Cell 1993; 72: 971–983.CrossRefGoogle Scholar
95. MacMillan, JC, Snell, RG, Tyler, A, Houlihan, GD, Fenton, I, et al. Molecular analysis and clinical correlations of the Huntington’s Disease mutation. Lancet 1993; 342: 954–958.CrossRefGoogle ScholarPubMed
96. Duyao, M, Ambrose, CM, Myers, RM, et al. Trinucleotide repeat length instability and age of onset in Huntington’s Disease. Nature Genetics 1993; 4: 387–392.CrossRefGoogle ScholarPubMed
97. Andrew, SE, Goldberg, YP, Kremer, B, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s Disease. Nature Genetics 1993; 4: 398–403.CrossRefGoogle ScholarPubMed
98. Goldberg, YP, Kremer, B, Andrew, et al. Molecular analysis of new mutations for Huntington’s Disease: intermediate alleles and sex of origin effects. Nature Genetics 1993; 5: 174–179.CrossRefGoogle ScholarPubMed
99. MacDonald, ME, Barnes, G, Srinidhi, J, et al. Gametic but not somatic instability of CAG repeat length in Huntington’s Disease. J Med Genet 1993; 30: 982–986.CrossRefGoogle Scholar
100. Myers, RH, MacDonald, ME, Koroshetz, WJ, Duyao, MP, Ambrose, CM, et al. De novo expansion of (CAG)n repeat in sporadic Huntington’s Disease. Nature Genetics 1993; 5: 168–173.CrossRefGoogle ScholarPubMed
101. Andrew, SE, Goldber, YP, Kremer, B, et al. Huntington Disease without CAG expansion: phenocopies or errors in assignment? Am J Hum Genet 1994; 54: 852–863.Google ScholarPubMed
102. Nagafuchi, S, et al. Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nature Genetics 1994; 6: 14–18.CrossRefGoogle ScholarPubMed
103. Koide, R, et al. Unstable expansion of CAG repeat in hereditary DRPLA. Nature Genetics 1994; 6: 9–13.CrossRefGoogle Scholar
104. Folstein, SE.Huntington’s Disease: A Disorder of Families. Baltimore: Johns Hopkins University Press, 1989.Google Scholar
105. Barr, AN, Fischer, JH, Roller, WC, et al. Serum haloperidol concentration and choreiform movements in Huntington’s disease. Neurology 1988; 38:84–88.CrossRefGoogle ScholarPubMed
106. Mastromauro, C, Myers, RH, Berkman, B.Attitudes toward presymptomatic testing in Huntington’s Disease. Am J Med Genet 1987; 26:271–282.CrossRefGoogle Scholar
107. Fox, S, Bloch, M, Fahy, M, Hayden, MR.Predictive testing for Huntington’s Disease. I. Description of a pilot project in British Columbia. Am J Med Genet 1989; 32: 211–216.CrossRefGoogle ScholarPubMed
108. Huggins, M, Bloch, M, Wiggins, S, et al. Prédictive testing of Huntington’s disease in Canada: Adverse effects and unexpected results in those receiving a decreased risk. Am J Med Genet 1992; 42:508–515.CrossRefGoogle ScholarPubMed
109. Wiggins, S, Whyte, P, Huggins, M, et al. The psychological consequences of predictive testing for Huntington’s disease. N Engl J Med 1992; 327: 1401–1405.CrossRefGoogle ScholarPubMed
110. World Federation of Neurology Research Group on Huntington’s Disease. Ethical issues policy statement on Huntington’s Disease molecular genetics predictive testing. J Med Genet 1990; 27: 34–38.CrossRefGoogle Scholar